Volatile anesthetics and liver injury: A clinical update or what every anesthesiologist should know;Les anesthésiques volatiles et l'atteinte hépatique: Une mise à jour clinique ou ce que tout anesthésiologiste devrait savoir

Canadian Journal of Anesthesia

Volumn 52, Issue 2, 2005, Pages 125-129

  Martin, Jackie L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROFLUOROHYDROCARBON; DESFLURANE; ENFLURANE; HALOTHANE; INHALATION ANESTHETIC AGENT; ISOFLURANE; NITROUS OXIDE; SEVOFLURANE; XENON;

ANESTHESIST; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG USE; EDITORIAL; HEMODYNAMICS; HEPATITIS; HUMAN; LIVER INJURY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 16344382934     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03027715     Document Type: Editorial

References (15)

1. Tung D, Yoshida EM, Wang CS, Steinbrecher UP. Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anesth 2005; 52: 133-6.
2. Njoku D, Laster MJ, Gong DH, et al. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth Analg 1997; 84: 173-8.
3. Hoet P, Graf ML, Bourdi M, et al. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 1997; 350: 556-9.
4. Harris JW, Pohl LR, Martin JL, Anders MW. Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trichloroethane. Proc Natl Acad Sci USA 1991; 88: 1407-10.
5. Sadove MS, Kim SI. Hepatitis after use of two different fluorinated anesthetic agents. Anesth Analg 1974; 53: 336-40.
6. Sigurdsson J, Hreidarsson AB, Thejodleifsson B. Enflurane hepatitis. A report of a case with a previous history of halothane hepatitis. Acta Anaesthesiol Scand 1985; 29: 495-6.
7. Christ DD, Kenna JG, Kammerer W, Satoh H, Pohl LR. Enflurane metabolism produces covalently bound liver adducts recognized by antibodies from patients with halothane hepatitis. Anesthesiology 1988; 69: 833-8.
8. Martin JL, Kenna JG, Pohl LR. Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 1990; 70: 154-9.
9. Martin JL, Keegan MT, Vasdev GM, et al. Fatal hepatitis associated with isoflurane exposure and CYP2A6 autoantibodies. Anesthesiology 2001; 95: 551-3.
10. Cousins MJ, Plummer JL, Hall PD. Risk factors for halothane hepatitis. Aust N Z Surg 1989; 59: 5-14.
11. Njoku DB, Greenberg RS, Bourdi M, et al. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg 2002; 94: 243-9.
12. Cullen SC, Gross EG. The anesthetic properties of xenon in animals and human beings, with additional observations on krypton. Science 1951; 113: 580-2.
13. Lachmann B, Armbruster S, Schairer W, et al. Safety and efficacy of xenon in routine use as an inhalational anaesthetic. Lancet 1990; 335: 1413-5.
14. Luttropp HH, Thomasson R, Dahm S, Persson J, Wernfr O. Clinical experience with minimal xenon anesthesia. Acta Anaesthesiol Scand 1994; 38: 121-5.
15. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 2003; 98: 6-13.